Journal
MOLECULAR AND CELLULAR ENDOCRINOLOGY
Volume 217, Issue 1-2, Pages 239-241Publisher
ELSEVIER SCI IRELAND LTD
DOI: 10.1016/j.mce.2003.10.024
Keywords
vasculopathy; RAAS; chronic heart failure
Categories
Ask authors/readers for more resources
Aldosterone antagonists reduce mortality in chronic heart failure (CHF). An obvious question to ask is how do they do this. The prevailing hypothesis is that most of the adverse effects of aldosterone stein from its ability to produce a vasculopathy. This vasculopathy is characterised by a reduction in vascular nitric oxide and may be produced by aldosterone's ability to generate superoxide radicals which degrade endogenous NO. The consequences of this aldosterone-induced vasculopathy are that it produces tissue ischaemia/infarction and injury, which then repairs itself by producing fibrosis. Aldosterone-induced vasculopathy may be the main mechanism why aldosterone promotes widespread tissue injury and ultimately cardiac death. (C) 2003 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available